New drug aims to keep platelets up during breast cancer chemo
NCT ID NCT07647029
First seen Jun 16, 2026 · Last updated Jun 21, 2026 · Updated 1 time
Summary
This phase 2 study tests whether the drug hetrombopag can prevent dangerously low platelet counts caused by chemotherapy in breast cancer patients at high risk. About 126 participants will be split into three groups: one getting no preventive drug, one taking hetrombopag continuously for two chemo cycles, and one taking it for 14 days each cycle. The main goal is to see if the drug reduces the number of patients who develop moderate to severe low platelets.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hetrombopag (a drug to boost platelet counts)
What this could lead to
If it works, this could point toward a way to prevent severe low platelet counts during chemotherapy, helping breast cancer patients complete their treatment on schedule.
What could go wrong
This is a small, early-phase trial (126 people) that has not started recruiting yet. The drug may not reduce low platelet events as hoped, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.